Phase i trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma

Abby B. Siegel, Anthony B. El-Khoueiry, Richard S. Finn, Katherine A. Guthrie, Abhishek Goyal, Alan P. Venook, Charles Blanke, Elizabeth C. Verna, Lorna Dove, Jean Emond, Tomoaki Kato, Benjamin Samstein, Ronald Busuttil, Helen Remotti, Amy Coffey, Robert S. Brown

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Liver transplantation offers excellent long-term survival for hepatocellular carcinoma (HCC) patients who fall within established criteria. For those outside such criteria, or with high-risk pathologic features in the explant, HCC recurrence rates are higher. We conducted a multicenter phase I trial of sorafenib in liver transplantation patients with high-risk HCC. Subjects had HCC outside the Milan criteria (pre- or post-transplant), poorly differentiated tumors, or vascular invasion. We used a standard 3+3 phase I design with a planned duration of treatment of 24 weeks. Correlative studies included the number of circulating endothelial cells (CECs), plasma biomarkers, and tumor expression of p-Erk, p-Akt, and c-Met in tissue micro-arrays. We enrolled 14 patients with a median age of 63 years. Of these, 93% were men and 71% had underlying hepatitis C virus (HCV) and 21% had HBV. The maximum tolerated dose of sorafenib was 200 mg BID. Grade 3-4 toxicities seen in >10% of subjects included leukopenia (21%), elevated gamma-glutamyl transferase (21%), hypertension (14%), hand-foot syndrome (14%) and diarrhea (14%). Over a median follow-up of 953 days, one patient died and four recurred. The mean CEC number at baseline was 21 cells/4 ml for those who recurred, and 80 cells/4 ml for those who did not (p=0.10). Mean soluble vascular endothelial growth factor receptor-2 levels decreased after 1 month on sorafenib (p=0.09), but did not correlate with recurrence. There was a trend for tumor c-Met expression to correlate with increased risk of recurrence. Post-transplant sorafenib was found to be feasible and tolerable at 200 mg PO BID. The effect of post-transplant sorafenib on recurrence-free survival is potentially promising but needs further validation in a larger study.

Original languageEnglish (US)
Pages (from-to)115-125
Number of pages11
JournalLiver Cancer
Volume4
Issue number2
DOIs
StatePublished - Apr 27 2015
Externally publishedYes

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Transplants
Recurrence
Endothelial Cells
Hand-Foot Syndrome
Vascular Endothelial Growth Factor Receptor-2
Survival
Maximum Tolerated Dose
Leukopenia
Tumor Biomarkers
Transferases
Hepacivirus
Blood Vessels
Diarrhea
Neoplasms
Cell Count
sorafenib
Hypertension
Therapeutics

Keywords

  • Hepatocellular carcinoma
  • High risk
  • Liver transplant
  • Phase I
  • Sorafenib

ASJC Scopus subject areas

  • Hepatology
  • Oncology

Cite this

Siegel, A. B., El-Khoueiry, A. B., Finn, R. S., Guthrie, K. A., Goyal, A., Venook, A. P., ... Brown, R. S. (2015). Phase i trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. Liver Cancer, 4(2), 115-125. https://doi.org/10.1159/000367734

Phase i trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. / Siegel, Abby B.; El-Khoueiry, Anthony B.; Finn, Richard S.; Guthrie, Katherine A.; Goyal, Abhishek; Venook, Alan P.; Blanke, Charles; Verna, Elizabeth C.; Dove, Lorna; Emond, Jean; Kato, Tomoaki; Samstein, Benjamin; Busuttil, Ronald; Remotti, Helen; Coffey, Amy; Brown, Robert S.

In: Liver Cancer, Vol. 4, No. 2, 27.04.2015, p. 115-125.

Research output: Contribution to journalArticle

Siegel, AB, El-Khoueiry, AB, Finn, RS, Guthrie, KA, Goyal, A, Venook, AP, Blanke, C, Verna, EC, Dove, L, Emond, J, Kato, T, Samstein, B, Busuttil, R, Remotti, H, Coffey, A & Brown, RS 2015, 'Phase i trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma', Liver Cancer, vol. 4, no. 2, pp. 115-125. https://doi.org/10.1159/000367734
Siegel AB, El-Khoueiry AB, Finn RS, Guthrie KA, Goyal A, Venook AP et al. Phase i trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. Liver Cancer. 2015 Apr 27;4(2):115-125. https://doi.org/10.1159/000367734
Siegel, Abby B. ; El-Khoueiry, Anthony B. ; Finn, Richard S. ; Guthrie, Katherine A. ; Goyal, Abhishek ; Venook, Alan P. ; Blanke, Charles ; Verna, Elizabeth C. ; Dove, Lorna ; Emond, Jean ; Kato, Tomoaki ; Samstein, Benjamin ; Busuttil, Ronald ; Remotti, Helen ; Coffey, Amy ; Brown, Robert S. / Phase i trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. In: Liver Cancer. 2015 ; Vol. 4, No. 2. pp. 115-125.
@article{9785cdd8e03d494383ebe02555a433a1,
title = "Phase i trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma",
abstract = "Liver transplantation offers excellent long-term survival for hepatocellular carcinoma (HCC) patients who fall within established criteria. For those outside such criteria, or with high-risk pathologic features in the explant, HCC recurrence rates are higher. We conducted a multicenter phase I trial of sorafenib in liver transplantation patients with high-risk HCC. Subjects had HCC outside the Milan criteria (pre- or post-transplant), poorly differentiated tumors, or vascular invasion. We used a standard 3+3 phase I design with a planned duration of treatment of 24 weeks. Correlative studies included the number of circulating endothelial cells (CECs), plasma biomarkers, and tumor expression of p-Erk, p-Akt, and c-Met in tissue micro-arrays. We enrolled 14 patients with a median age of 63 years. Of these, 93{\%} were men and 71{\%} had underlying hepatitis C virus (HCV) and 21{\%} had HBV. The maximum tolerated dose of sorafenib was 200 mg BID. Grade 3-4 toxicities seen in >10{\%} of subjects included leukopenia (21{\%}), elevated gamma-glutamyl transferase (21{\%}), hypertension (14{\%}), hand-foot syndrome (14{\%}) and diarrhea (14{\%}). Over a median follow-up of 953 days, one patient died and four recurred. The mean CEC number at baseline was 21 cells/4 ml for those who recurred, and 80 cells/4 ml for those who did not (p=0.10). Mean soluble vascular endothelial growth factor receptor-2 levels decreased after 1 month on sorafenib (p=0.09), but did not correlate with recurrence. There was a trend for tumor c-Met expression to correlate with increased risk of recurrence. Post-transplant sorafenib was found to be feasible and tolerable at 200 mg PO BID. The effect of post-transplant sorafenib on recurrence-free survival is potentially promising but needs further validation in a larger study.",
keywords = "Hepatocellular carcinoma, High risk, Liver transplant, Phase I, Sorafenib",
author = "Siegel, {Abby B.} and El-Khoueiry, {Anthony B.} and Finn, {Richard S.} and Guthrie, {Katherine A.} and Abhishek Goyal and Venook, {Alan P.} and Charles Blanke and Verna, {Elizabeth C.} and Lorna Dove and Jean Emond and Tomoaki Kato and Benjamin Samstein and Ronald Busuttil and Helen Remotti and Amy Coffey and Brown, {Robert S.}",
year = "2015",
month = "4",
day = "27",
doi = "10.1159/000367734",
language = "English (US)",
volume = "4",
pages = "115--125",
journal = "Liver Cancer",
issn = "2235-1795",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Phase i trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma

AU - Siegel, Abby B.

AU - El-Khoueiry, Anthony B.

AU - Finn, Richard S.

AU - Guthrie, Katherine A.

AU - Goyal, Abhishek

AU - Venook, Alan P.

AU - Blanke, Charles

AU - Verna, Elizabeth C.

AU - Dove, Lorna

AU - Emond, Jean

AU - Kato, Tomoaki

AU - Samstein, Benjamin

AU - Busuttil, Ronald

AU - Remotti, Helen

AU - Coffey, Amy

AU - Brown, Robert S.

PY - 2015/4/27

Y1 - 2015/4/27

N2 - Liver transplantation offers excellent long-term survival for hepatocellular carcinoma (HCC) patients who fall within established criteria. For those outside such criteria, or with high-risk pathologic features in the explant, HCC recurrence rates are higher. We conducted a multicenter phase I trial of sorafenib in liver transplantation patients with high-risk HCC. Subjects had HCC outside the Milan criteria (pre- or post-transplant), poorly differentiated tumors, or vascular invasion. We used a standard 3+3 phase I design with a planned duration of treatment of 24 weeks. Correlative studies included the number of circulating endothelial cells (CECs), plasma biomarkers, and tumor expression of p-Erk, p-Akt, and c-Met in tissue micro-arrays. We enrolled 14 patients with a median age of 63 years. Of these, 93% were men and 71% had underlying hepatitis C virus (HCV) and 21% had HBV. The maximum tolerated dose of sorafenib was 200 mg BID. Grade 3-4 toxicities seen in >10% of subjects included leukopenia (21%), elevated gamma-glutamyl transferase (21%), hypertension (14%), hand-foot syndrome (14%) and diarrhea (14%). Over a median follow-up of 953 days, one patient died and four recurred. The mean CEC number at baseline was 21 cells/4 ml for those who recurred, and 80 cells/4 ml for those who did not (p=0.10). Mean soluble vascular endothelial growth factor receptor-2 levels decreased after 1 month on sorafenib (p=0.09), but did not correlate with recurrence. There was a trend for tumor c-Met expression to correlate with increased risk of recurrence. Post-transplant sorafenib was found to be feasible and tolerable at 200 mg PO BID. The effect of post-transplant sorafenib on recurrence-free survival is potentially promising but needs further validation in a larger study.

AB - Liver transplantation offers excellent long-term survival for hepatocellular carcinoma (HCC) patients who fall within established criteria. For those outside such criteria, or with high-risk pathologic features in the explant, HCC recurrence rates are higher. We conducted a multicenter phase I trial of sorafenib in liver transplantation patients with high-risk HCC. Subjects had HCC outside the Milan criteria (pre- or post-transplant), poorly differentiated tumors, or vascular invasion. We used a standard 3+3 phase I design with a planned duration of treatment of 24 weeks. Correlative studies included the number of circulating endothelial cells (CECs), plasma biomarkers, and tumor expression of p-Erk, p-Akt, and c-Met in tissue micro-arrays. We enrolled 14 patients with a median age of 63 years. Of these, 93% were men and 71% had underlying hepatitis C virus (HCV) and 21% had HBV. The maximum tolerated dose of sorafenib was 200 mg BID. Grade 3-4 toxicities seen in >10% of subjects included leukopenia (21%), elevated gamma-glutamyl transferase (21%), hypertension (14%), hand-foot syndrome (14%) and diarrhea (14%). Over a median follow-up of 953 days, one patient died and four recurred. The mean CEC number at baseline was 21 cells/4 ml for those who recurred, and 80 cells/4 ml for those who did not (p=0.10). Mean soluble vascular endothelial growth factor receptor-2 levels decreased after 1 month on sorafenib (p=0.09), but did not correlate with recurrence. There was a trend for tumor c-Met expression to correlate with increased risk of recurrence. Post-transplant sorafenib was found to be feasible and tolerable at 200 mg PO BID. The effect of post-transplant sorafenib on recurrence-free survival is potentially promising but needs further validation in a larger study.

KW - Hepatocellular carcinoma

KW - High risk

KW - Liver transplant

KW - Phase I

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84945121093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945121093&partnerID=8YFLogxK

U2 - 10.1159/000367734

DO - 10.1159/000367734

M3 - Article

VL - 4

SP - 115

EP - 125

JO - Liver Cancer

JF - Liver Cancer

SN - 2235-1795

IS - 2

ER -